

Submission ID	Abstract Title	Presenter	Poster ID
6	Barriers to the diagnosis of motor neuron dis	Dale Sharrad	DSP-01
7	Support for Patients with Intractable Neurolo	Masako Nagase	CP-21
8	A clinical tool to determine the probability of	Puja Mehta	GEN-02
10	OT for people with MND: Adjusting and adap	Sarah Solomon	CP-27
11	Phosphoneurofilament heavy chain and IgG	Julia Costa	BIO-05
12	Reassessment of Split-Leg Signs in Amyotro	Zhi-Li Wang	IMG-03
13	Split-hand index for amyotrophic lateral scler	Zhi-Li Wang	IMG-04
14	Characterising CYTSB as a potential therape	Roxanna Munir	WP-11
15	The Impact of Frequent Sampling of New and	Jeremy Shefner	CLT-10
17	Abnormal Accumulation of Citrullinated Prote	YASUMASA KOKUBO	HCB-23
18	Increased Interleukin-6 levels in the astrocyte	Yong Chen	BIO-15
20	COMBINED BONE MARROW TRANSPLANT	Tomoya Terashima	TST-23
22	Increased levels of a key UPS protein reduce	Isabella Lambert-Smith	IVT-20
24	Prevalence of Amyotrophic Lateral Sclerosis	Paul Mehta	WP-01
25	Utilizing Capture-Recapture Methodology to	Kevin Horton	WP-02
26	Augmentative and Alternative Communicatio	Gerson Chadi	COG-14
27	Pharmacological modulation of hypermetabo	Alberto Ferri	TST-34
29	ALS-associated Mutations in the TDP-43 Lov	Luke McAlary	IVT-32
30	Critical epochs of environmental exposures a	Walter Bradley	WP-03
31	Clinical usefulness of neuropsychological sca	KAZUAKI NAGASHIMA	COG-07
32	Implication of rare variants in causative gene	Yuka Hama	GEN-03
33	Differentiating needs of informal caregivers c	Christopher Poppe	CP-13
34	Applying Mendelian Randomization Methods	Carmel Armon	EPI-01
37	Exome analysis in 54 autopsied Japanese sp	Tomohiko Ishihara	GEN-09
38	A novel splicing variant of ANXA11 in Japane	Yuya Hatano	GEN-11
39	Converging pathological mechanisms in ALS	Laura Fort	IVV-41
40	High-content screening platform to screen p	Prachi Mehta	IVT-02
41	Genetic and functional analysis of the KIF5A	Ryoichi Nakamura	GEN-10
43	Assessing preference heterogeneity with res	Michelle Farrar	CP-22
44	The split hand sign in spinal and bulbar musc	Kazumoto Shibuya	IMG-05
46	Ubiquitin homeostasis is disrupted in ALS	Natalie Farrowell	IVT-21
48	Neuronal Toxicity and Mitochondrial Protecti	Kohji Fukunaga	IVT-24
50	Temporal variation of anthropometric param	Cristina Cleide dos Salvioni	RNM-02
51	A Phase 1b, Open-Label, Dose-Escalation, S	Robert Henderson	CLT-34
54	Safety and biological efficacy of narrow-banc	Fiona McKay	CLT-28
55	Prognosis of TIV therapy for ALS patients in	Naoki Hayashi	RNM-25
56	Non-genetic origins of SOD1 protein misfold	Benjamin Trist	HCB-26
57	Significance of TDP-43, NfL, and tau in plas	Takuma Ohmichi	BIO-07
58	The impact of gastrointestinal related sympto	Elly Zandi	CP-06
59	Intranasal Oxytocin for Terminal ALS with Sc	Kazuki Fujita	WP-20
60	Biomarkers in cerebrospinal fluid for diagnos	Markus Axelsson	BIO-08
61	Assessment of upper motor neuron in ALS a	Juuri Otsuka	IMG-13

62	Elucidating axonal pathology of fused in sarc	Naoki Suzuki	HCB-12
63	Fasciculations demonstrate daytime consiste	James Bashford	IMG-08
64	Bioequivalence of CuATSM Capsule and Ora	Kay Noel	CLT-36
65	Providing collars for people with Motor Neur	Rosanne Gibb	CMS-16
66	How an Occupational Therapy service has ch	Renae Knight	CP-26
67	How open ended questions posed by clients	Renae Knight	CP-25
68	Shhh...we don't talk about that !	Lois Quick	CP-30
69	Factors associated with oral nutritional behav	Christopher McDermott	RNM-03
71	Metro South Chronic Disease MND Gastrost	Lois Quick	CP-31
75	Four Quadrants of Care	Lois Quick	CP-29
77	Modelling cortical motor neuron pathology in	Zhefan Stephen Chen	HCB-04
78	Mental Health Support Plans For People Affe	Andrew Bethell	CP-19
81	The Vitamin D Activator, CYP27B1, is a Nove	Ying Si	BIO-03
83	Pharmacological autophagy induction cause	Isabella Lambert-Smith	IVT-19
85	A MICRODEVICE-BASED METHOD FOR QU	Shinji Hadano	IVT-25
86	Functional impairment and survival predictio	Adriano Chio	EPI-15
87	Redox-enhancing nanocatalysis improves me	Karen Ho	TST-35
88	Phase 1/2a, Double-blind, Placebo-controlle	Shinichi Takahashi	WP-16
89	Health utility decline with advancing FT9 sta	Erik Pioro	EPI-14
90	Serum albumin as an indicator of gastrostom	Jiwon Yang	RNM-04
91	Investigating the therapeutic potential of miR	Stavroula Tsitkanou	TST-05
92	The elucidation of disease mechanisms unde	Midhat Salman	GEN-08
94	Respiratory impairment is associated with co	William Huynh	COG-05
95	Impaired NHEJ repair in Amyotrophic Latera	Anna Konopka	IVT-28
96	Phenotypic variation in ALS-FTD and effect	Rebekah Ahmed	COG-01
98	Cognitive and behavioural changes predict p	Chilan Nguyen	COG-02
99	Genotype Characteristics of Patients with An	Qi Niu	GEN-18
100	Optimizing the ALSFRS-R as a clinical trial e	Ruben van Eijk	CLT-14
101	Weight stability is associated with longer sur	Qianqian Wei	RNM-01
102	Assessing the impact of genetic information	Harry Bowles	EPI-12
105	DEVELOPMENT OF AUTOPHAGY-INDUCIN	Azin Amin	TST-18
106	Can modulation of the gut microbiota confer	Karen Garnaas	CLT-33
107	Is The Problem Within The Gut Instead of the	Karen Garnaas	BIO-01
108	CNS-derived extracellular vesicles from supe	Neil Cashman	HCB-25
109	Familial Amyotrophic Lateral Sclerosis (ALS)	Ashley Crook	CP-12
110	Genetic testing for familial amyotrophic later	Ashley Crook	CMS-01
111	The Demographic and Clinical Characteristic	Nur Adilah Abdul-Aziz	DSP-12
112	Preventing amyotrophic lateral sclerosis (ALS)	Ashley Crook	CMS-02
113	Sleep-Disordered Breathing Can Be Asympt	Nur Adilah Abdul Aziz	RNM-13
114	Respiratory function and infections in people	Nicole Sheers	RNM-16
115	Investigating the genetics of Amyotrophic La	Suzanna Edgar	GEN-22
116	Pneumothorax in neuromuscular disease ass	Nicole Sheers	CP-10
117	Mutation analysis of the GLT8D1and ARPP2	Junling Wang	GEN-17
119	A novel cell transplantation therapy for famili	Sumio Minamiyama	TST-13
120	Changes in diurnal and nocturnal activity occ	Diana Lucia	CMS-05
121	Cognition and behavior in Japanese ALS pat	Yasuhiro Watanabe	COG-06

122	Significant out-of-sample classification from machine learning	Marta Nabais	BIO-09
124	Machine learning for novel prognosis prediction in amyotrophic lateral sclerosis	Vincent Grollemund	WP-19
125	An example of possibility for family members to participate in clinical trials	Kana Adachi	CMS-13
126	Information needs and Resource preferences of people with amyotrophic lateral sclerosis	Hyeon Sik Chu	CMS-14
127	The Japanese Early-Stage Trial of High Dose Riluzole in Amyotrophic Lateral Sclerosis	Ryosuke Oki	WP-17
128	Reflections on the care of people with MND / Amyotrophic Lateral Sclerosis	David Oliver	CP-28
129	Combination of acamprosate and baclofen: a promising approach for the treatment of alcohol dependence	Rodolphe Hajj	TST-42
130	Amount of publicly available survey information on amyotrophic lateral sclerosis	Keiko Fukuroku	RNM-24
131	Clinical trial design for a Phase II, randomized, controlled trial of riluzole in amyotrophic lateral sclerosis	Sabrina Paganoni	CLT-24
132	Googling global burden of motor neuron disease	Thanh Phan	EPI-11
133	Single copy expression of mutant TDP-43 in amyotrophic lateral sclerosis	Jayden Clark	IVT-26
135	Long-term outcomes of gastrostomy in patients with amyotrophic lateral sclerosis	Seok-Jin Choi	RNM-05
137	Characterisation of the role of Annexin A11 in amyotrophic lateral sclerosis	Ricky Patel	IVT-34
138	Dystrophy Pattern of Motor Cortex in Amyotrophic Lateral Sclerosis	Dongchao Shen	IMG-24
139	Sequestration of RNA helicase DHX30 from mutant TDP-43 in amyotrophic lateral sclerosis	Ryota Hikiami	HCB-11
140	The homeoprotein transcription factor ENGR-1 is a novel marker for amyotrophic lateral sclerosis	Stephanie Vargas Abonce	TST-16
141	Study AB19001, a confirmatory, pivotal phase III trial of riluzole in amyotrophic lateral sclerosis	Angela Genge	CLT-19
142	MND Register for England, Wales and Northern Ireland	Sarah Opie-Martin	EPI-09
144	The ALS GAP Program: Paving the Way for Clinical Trials	Jennifer Roggenbuck	GEN-01
145	Improvements in the definition of biomarkers for amyotrophic lateral sclerosis	Giorgia Querin	DSP-04
148	Robot-assisted training using Hybrid Assistive Limb in amyotrophic lateral sclerosis	Osamu Kano	CMS-09
150	Cessation of Driving in Individuals with Amyotrophic Lateral Sclerosis	Heather Hayes	CMS-11
152	Motor symptoms and physical activity assessment in amyotrophic lateral sclerosis	Gerson Chadi	CMS-07
153	MSC-NTF Differentiation Increases the Neuroprotective Capacity of Motor Neurons	Ralph Kern	IVT-11
154	Utilization of Durable Medical Equipment in Frontotemporal Dementia	Stacy Rudnicki	CLT-20
155	Responder and Subgroup Analyses for Frontotemporal Dementia	Jeremy Shefner	CLT-21
156	Quality of Life and Depression Measurement in Frontotemporal Dementia	Stacy Rudnicki	CLT-22
157	Impact of ALSFRS-R progression rates on quality of life in frontotemporal dementia	Stacy Rudnicki	CLT-23
158	Predicting disease-specific spinal motor neuron loss in amyotrophic lateral sclerosis	Fei Song	HCB-21
159	Ectopic impulse generation in peripheral nerves in amyotrophic lateral sclerosis	Yu-ichi Noto	IMG-11
160	Characterising the role of SARM1 in ALS and frontotemporal dementia	Sharn Perry	BIO-10
161	Microglia specific and disease associated protein expression in frontotemporal dementia	Romina Barreto-Núñez	IVV-16
163	RNA trafficking is disrupted in oligodendrocytes in frontotemporal dementia	Samantha Barton	HCB-24
165	Network aberrations in iTDP-43A315T mouse model of frontotemporal dementia	Annika van Hummel	IVV-37
166	Sorting cells with ALS-associated protein aggregates	Rebecca San Gil	IVT-04
167	Motor neuron disease with malignancy: a pathologic entity	Mana Higashihara	IMG-14
168	Using Next Generation Sequencing and functional genomics to identify novel ALS genes	Sandrine Chan Moi Fat	GEN-28
170	Viral strategies for pre-clinical testing in the treatment of amyotrophic lateral sclerosis	Heledd Brown-Wright	TST-28
173	Selecting Appropriate Outcome Measures for Clinical Trials in Amyotrophic Lateral Sclerosis	Omar Dabbous	CLT-13
174	TDP-43 mutant lacking its C-terminal domain is more neurotoxic	Seiji Watanabe	IVV-07
176	EPI-589, a novel redox-active protectant against oxidative stress	Rika Motodate	IVT-23
177	The TGF-beta induced muscle fibrosis and weakness in amyotrophic lateral sclerosis	Young Nam Kwon	IVT-37
178	A systematic review of diet and exercise clinical trials in amyotrophic lateral sclerosis	Elizabeth Zheng	CP-04
181	Beneficial effects of EPI-589, a novel redox-active protectant against oxidative stress	Tetsuaki Nashida	IVV-11
182	Co-administration of EPI-589, a novel redox-active protectant against oxidative stress	Yuji Matsumoto	IVV-12
183	Investigating Antisense Oligonucleotide Therapy in Amyotrophic Lateral Sclerosis	Rita Mejzini	TST-07

184	Gross numbers of letters as the effect of a sh	Takemasa Ishikawa	CMS-22
185	Vitamin levels in patients with amyotrophic la	Junling Wang	BIO-02
186	Layer V Pyramidal Neurons with synaptic hyp	Jonu Pradhan	IVT-18
187	Cortical thickness, white matter graph netwo	Erik Pioro	IMG-23
188	Diagnostic utility of the split-hand index in AL	Andrew Hannaford	WP-13
189	Possibility of needle EMG for prognostic prec	Yoko Sato	EPI-16
190	Distribution patterns of fasciculations in amy	Yo-ichi Suzuki	IMG-10
191	Can MRI Enable an Earlier or more Certain D	Thomas Welton	IMG-19
194	The pathogenic role of a new FUS isoform in	Marta Vidal	HCB-13
195	Validation study of clinical diagnosis of amy	Tomoyasu Matsubara	DSP-02
196	Neuropeptide Y reduces cell death in vitro vi	Courtney Clark	IVT-16
197	Mutant Protein aggregates, mitochondrial im	Min Deng	IVT-10
199	Enhancing glycosphingolipid metabolism imp	Sophia Luikinga	IVV-20
200	Frequency and methylation status of active L	Abigail Pfaff	GEN-26
201	First De novo SOD1 Pathogenic Variant in K	Young-Eun Kim	GEN-23
202	Immunogenes for targeted neurotrophic fact	Mary-Louise Rogers	TST-24
203	Enhanced survival of a transplanted MSC sho	Naoto Honda	IVV-36
204	The clinical phenotype of motor neuron disea	Thomas Jenkins	DSP-11
205	Diaphragm pacing impairs local myofiber rei	Gaëlle Bruneteau	RNM-21
206	TIA1 interacts with mutant SOD1 and affects	Gye Sun Jeon	IVT-15
207	SQSTM1/p62 expression induces TDP-43 cy	Sarah Rea	IVT-30
208	Longitudinal assessment of individual muscle	Thomas Jenkins	IMG-12
209	Defective glucose metabolism in the brain ar	Tesfaye Tefera	IVV-22
210	Amyotrophic lateral sclerosis (ALS): a compl	Anne Gieseler	HCB-01
211	Ambroxol hydrochloride improves motor fun	Alexandra Bouscary	TST-04
212	TDP-43 mutation affects stress granule asse	Qiao Ding	IVT-14
213	Baseline characteristics and status update of	Chris Garratt	CLT-18
214	Interventions targeting the psychological wel	Paul Cafarella	CP-16
215	Relationship between EMG-detected fascicul	Kota Bokuda	IMG-07
216	Discussing Personalised Prognosis in Amyot	Remko van Eenennaam	CMS-31
217	Promotion of the Maturation of SOD1-FALS	Victoria Shephard	IVT-17
218	Using fluorescence microscopy techniques t	Naunehal Matharu	IVT-33
219	BDNF-regulation of in vivo axonal transport	Andrew Tosolini	IVV-28
225	Understanding the needs of ALS caregivers	Sile Carney	COG-13
226	A combined structural, functional and neuroc	Evan Edmond	WP-12
227	Involvement of complement system in meser	Gerson Chadi	CLT-31
228	The Role of Relationships and Social Support	Sile Carney	COG-12
229	Comparative analysys of the types of alternat	Adriana Oda	RNM-06
230	Remote Longitudinal Assessment of Function	Jeffrey Statland	CLT-11
232	Clinical Effects of two intrathecal infusions	Gerson Chadi	CLT-30
234	In vivo study of microglial-mediated clearanc	Andres Vidal-Itriago	IVV-17
235	Cognitive reserve as a mediator of cognitive	Emmet Costello	COG-03
236	A panel of three ratios of four molecules as c	Jessica Maximino	BIO-06
237	Regulation of motor neuron neurotrophic mo	Jessica Maximino	CLT-29
238	Estimate of an Acthar® Gel Treatment Effect	David Ennist	CLT-27
241	A Platform Trial for ALS: Innovative Trial Des	Sabrina Paganoni	CLT-05

242	Novel mutations in the cargo binding and sta	Zhangyu Zou	GEN-13
245	Familial flail leg amyotrophic lateral sclerosis	Zhang-Yu Zou	GEN-14
246	Comparison of Voluntary and Reflex Cough I	Lauren Tabor Gray	RNM-09
247	THE PATHOGENESIS OF CHLOROVIRUS IN	Gary Pattee	IVV-14
248	Fasciculation analysis reveals a novel advers	Kate Wannop	IMG-09
249	A CLINICAL BULBAR ASSESSMENT SCALE	Gary Pattee	CMS-19
252	UCHL1 is necessary and sufficient for mainte	Hande Ozdinler	TST-02
254	Identifying novel roles for Protein Disulfide Is	Sina Shadfar	IVV-27
255	Oscillating PeP (O-PeP) Devices versus Expi	Daniel Mergner	CP-09
256	CD34+ microglia precursors as therapeutic t	Luis Barbeito	TST-38
257	Identification of cellular targets of masitinib a	Emiliano Trias	TST-40
259	Elevated expression of the DNA/RNA-binding	Brigid Jensen	IVV-08
260	The needs and psychological distress of fam	Lone Knudsen	CP-20
261	Exosomes secreted by diseased ALS cerebr	Hande Ozdinler	IVT-31
262	Post-paralysis treatment with the synthetic in	Emiliano Trias	TST-39
264	Gait initiation and motor preparation are impa	Pierre-Francois Pradat	IMG-25
265	What Matters Most to Patients with ALS: Initia	Chad Heatwole	DSP-16
267	Design of the Australian Multicenter, Randon	Kay Noel	CLT-35
268	A Preliminary Analysis of the Feasibility and I	Eduardo Locatelli	CMS-30
269	The impact of Ryanodine receptor on organe	Benjamin Vlad	IVT-08
270	Impact of stimulus duration on detecting enla	Boudewijn Sleutjes	IMG-02
271	Tracking Bulbar Impairment Using the Beiwe	James Berry	DSP-14
272	Correlation between forced vital capacity (F	Alessandra Dorca	RNM-11
273	Family caregivers in ALS and their vital need	Martine Verwey	CP-14
275	Resistant neuromuscular junction of extraocu	Frederic Provost	IVV-24
276	Arimoclomol is neuroprotective and ameliora	Linda Greensmith	TST-36
277	Identity by descent analysis of Australian SO	Lyndal Henden	GEN-24
278	Degeneration of ALS mouse neuromuscular	Hiroshi Nishimune	TST-22
279	Cardiac Troponins as Biomarkers in Amyotro	Patrick Weydt	BIO-16
281	Modeling gene-toxicant interactions in amyot	Jessica Morrice	IVV-34
282	PHOSPHORYLATION STATE OF ALS2/ALS	Kento Shimakura	HCB-18
284	Proposition for the assessment of peak cough	Adriana Oda	RNM-22
285	Early Treatment Effects of Riluzole in ALS-MI	Benjamin Rix Brooks	COG-09
286	Subcortical abnormality is a prominent indica	Sicong Tu	IMG-20
287	Clinical criteria for the recommendation of in	Adriana Oda	RNM-23
288	Interaction between decline of swallowing an	Rebecca Francis	CMS-18
290	Role of C9orf72 in inflammation and neurode	Madelyn McCauley	IVV-39
291	Early Treatment Effects of Riluzole in ALS-MI	Benjamin Rix Brooks	DSP-17
292	Zydis Riluzole 40mg Oral Disintegrating Tabl	Johnny Jones	CMS-28
293	Foreign Accent Syndrome (FAS) and Amyotro	Adriana Oda	DSP-15
295	Hyperexcitable Layer 5 Pyramidal Neurons In	Marcus Dyer	IVV-10
296	Developing a web-based patient decision aid	Anne Hogden	CP-07
297	Development of the Online Carer's Question	Gail Robinson	COG-11
298	Does mislocalised TDP-43 in excitatory neur	Laura Reale	IVV-32
299	ANXA11 Mutations in ALS Cause Dysregulat	Su Min Lim	IVT-35
301	Understanding and Incorporating the Patient	Meghan McKenzie	CLT-02

302	An Inducible Zebrafish Model of Sporadic Ne	Emily Don	IVV-03
303	Neuronal Expression and Function of C-type	Minyeop Nahm	IVT-36
304	Exploration of N-Alkylated Carbazole Translo	Hei Wun Alison Cheng	BIO-14
305	The genotype and phenotype spectrum of fa	XUNZHE YANG	DSP-13
306	Targeting ALS cortical excitability dysfunctio	Katherine Lewis	TST-17
309	Date of Onset as an Indicator and Predictor o	Alexander Sherman	CLT-08
310	The level of functional hydration assessment	Adriana Oda	RNM-07
311	ALS2 ALONG WITH A NOVEL ALS2 INTERA	Asako Otomo	IVT-03
313	On-the-spot assessment of venous creatinine	Cory Holdom	DSP-05
316	Aspiring to Minimise Aspiration: Prevalence &	Pippa Klein	CMS-15
318	Biomarker analysis in oral levosimendan pha	Kira Holmström	BIO-11
319	Investigating NPY receptors in SOD1G93A tr	Rosemary Clark	IVV-38
320	MND phenotypes and premorbid status in th	Tore Meisingset	WP-04
321	C9orf72 is an actin binding protein involved i	Cyril Jagaraj	HCB-08
322	The development of a Multidisciplinary Spec	Alicia Gibb	CP-23
323	Genetic variation in known ALS genes is pre	Emily McCann	GEN-25
327	Longitudinal transcriptomic analysis of altere	Frédérique René	IVV-43
328	In vivo analysis of variant pathogenicity for th	ALISON HOGAN	IVV-02
329	Investigating hidden Gelsolin amyloidosis wh	Jinseok Park	DSP-03
331	A Large-Scale Library of Patient Derived iPS	Christopher Bye	HCB-02
332	Development and validation of Cas9 neurobl	Juliana Venturato	IVT-05
333	Optimisation of a method for the direct repro	Timothy Tracey	IVT-07
335	THE CAUSE OF DEATH IN PATHOLOGICAL	Kiyonobu Komai	RNM-27
336	Investigation of a novel genomic structural va	Leanne Jiang	GEN-07
337	Mechanism of Action of the Cardiovascular L	Kira Holmström	TST-43
338	Impaired glucose handling contributes to ske	Tanya McDonald	IVV-23
340	A single adjustment of the scanning-speed o	Yuji Tanaka	CMS-21
341	Investigating the role of oxidative stress in sp	Natalie Scherer	IVV-13
343	Elemental and structural characterisation of S	Sian Genoud	HCB-22
344	CRISPR-Cas9 mediated introduction of the T	Timothy Tracey	IVT-06
345	Cyclin F interacts with autophagy protein sec	Jennilee Davidson	IVT-22
346	Oral levosimendan for amyotrophic lateral sc	Valtteri Aho	CLT-26
348	Assessing structural- and copy number- varia	Jennifer Fifita	WP-05
349	Tracking ALS progression in clinical trials wit	Gabriela Stegmann	CLT-09
350	Tract pathology in amyotrophic lateral sclero	Robert Steinbach	IMG-21
351	Cull(ATSM) potently inhibits neuronal ferropt	Ashley Bush	TST-11
352	The Identification of scFv Biomolecules that I	Rudolf Hergesheimer	TST-14
354	The spectrum of involuntary movements in p	Blaž Koritnik	IMG-01
356	Transmissibility of SOD1 prion strains betwe	Thomas Brannstrom	IVV-26
357	Advantages of Southern blot to overcome re	Kevin Mouzat	GEN-05
358	Interplay of necroptotic and ferroptotic mot	Ted Wang	IVV-30
359	Exploration of genetic architecture in Chines	Kang Zhang	GEN-15
360	ALS-associated TBK1 variant p.G175S is unc	Adriana Foster	GEN-20
361	Novel method to detect DNA damage in ALS	Mariana Brocardo	HCB-07
362	New Strategy for Blood-Brain Barrier Crossin	BINGYANG SHI	TST-26
363	Assessing Cortico-Muscular Communication	Roisin McMackin	IMG-16

364	ALS and full-marathon : responce to edaravoc	Hiide Yoshino	CP-02
366	Genetic and immunopathological analysis of	Shu Yang	HCB-19
367	A survey exploring the practice of healthcare	Theocharis Stavroulakis	RNM-18
369	Repeated Intrathecal Allogeneic Bone Marro	Seung Hyun Kim	CLT-32
370	Efficacy of a group-based mindfulness progr	Catherine Gluyas	CP-17
371	Ca ²⁺ -activated K ⁺ channels modulate micro	Germana Coccozza	TST-37
372	MND- Respiratory supports: the impact of no	Shyamala Pradeepan	RNM-20
373	Developing new cell models and approaches	Sean Keating	TST-19
374	Oral glutathione administration rescues neur	Reiko Fukunaga	IVV-18
375	Use of Zebrafish for the functional validation	Kevin Mouzat	IVV-01
376	Targeted long-read sequencing of C9orf72 r	Matthew Parker	GEN-06
379	A protective role for complement C3aR activ	John Lee	IVV-15
380	Establishing a novel mouse model of sporadi	Mouna Haidar	IVV-09
381	Investigating the Role of TDP-43 Recruitmen	George Wardley	IVV-33
382	A functional pipeline for the validation of nov	Shu Yang	IVT-01
383	Clinical Implications of Upper Esophageal Sp	Charles Cock	CMS-17
384	Mutation analysis of causative genes for amy	Jun Wang	GEN-16
385	Group Interventions for ALS Caregivers: A R	Tom Burke	CP-15
386	Virtual Reality in ALS	Scott Vota	CMS-24
388	In vitro measurement of molecular vibrationa	Yu Nagashima	IVT-38
389	Overhauling clinical trials for amyotrophic lat	Ruben van Eijk	CLT-15
390	Retaining Voice Identity in ALS/MND patients	Rohan Chopra	EPI-19
391	Clinical characteristics of young-onset amyot	Sanggon Lee	WP-18
392	Targeting ATXN2 with artificial microRNA as	Sarah Freckleton	TST-06
394	People living with ALS and their caregivers' i	Orla Hardiman	WP-14
397	Genetic origin of ALS: a somatic or germinal	Alberto García-Redondo	GEN-27
399	A PILOT PROJECT TO DETERMINE IF STAN	AJAY PAUL	CP-03
400	Assessing TDP-43 and RNA dynamics; patien	Erin Hedges	HCB-14
402	Treatment with HDAC inhibitors is protective	Angela Laird	TST-29
403	Improved survival in Amyotrophic Lateral Sc	Hemangi Sane	CMS-25
404	Increasing the Efficiency of ALS Clinical Trial	David Ennist	CLT-06
405	The ALS Steering Wheel: A Multidisciplinary	Kristiana Salmon	CMS-10
406	A Novel Mutation of Endoplasmic Reticulum	ChunYu Li	IVT-39
407	Pre-clinical development of a genetic therapy	Loren Flynn	TST-08
408	An investigation into whether board certified	Mieko Ogino	CMS-12
410	A SYSTEMATIC REVIEW OF THE ROLE OF	Radhika Pradhan	TST-21
411	NF-κB activation in astroglia in mouse model	Carsten Kroeger	WP-08
412	Antisense Oligonucleotide Modulation of Sel	Ilanthe Pitout	TST-09
413	EPIDEMIOLOGICAL STUDY OF MOTOR NE	Amruta Paranjape	EPI-07
414	Screening of the OPTN mutations in Chinese	Lu Yang	GEN-19
415	ANXA11 Mutations are commonly associated	Zhangyu Zou	GEN-12
416	Characterization of mice with heterozygous T	Clara Bruno	IVV-06
417	Heterozygous Tbk1 deletion in a TARDBP m	Clara Bruno	IVV-05
418	The safety of PEG in patients with ALS using	Naomi Tominaga	RNM-08
420	Design of the Phase 3, Randomised, Placebo	Claus Sundgreen	CLT-16
421	Shared genetic architecture between ALS, b	Ross Byrne	GEN-04

422	The diagnostic experience in MND; a UK sur	Mary O'Brien	CMS-04
423	Investigation of HSF1 Gene Therapy in a mo	Conor McLoughlin	IVV-35
424	Subcutaneous infusion of next generation ne	Liam Beckett	TST-25
426	Symptoms of hypoventilation most sensitive	Jochem Helleman	RNM-15
427	Quantifying Cognitive and Motor Preparatory	Roisin McMackin	IMG-18
429	Incidence of MND/ALS in the Western Cape	Franco Henning	EPI-06
431	The MotOrtose project - Development of a m	Tore Meisingset	WP-23
432	Developing Biomarkers of Focal Network Dis	Roisin McMackin	IMG-17
433	Verification of the effect of medical coordinat	Miyuki Hotta	CMS-23
434	Do cognitive or behavioural problems explain	Dorothee Lulé	COG-04
435	A systematic review of cognitive screening to	Emily Mayberry	COG-10
436	Restoration of histone acetylation ameliorate	Ludo Van Den Bosch	TST-30
438	tRNA modification defects in mouse models	Marion Hogg	IVV-42
440	The potential of neurofilaments analysis usin	Vittoria Lombardi	TST-01
441	A multicentric approach to monocyte alterati	Sarah Brockmann	HCB-15
443	Blood-brain barrier disruption is associated	Benjamin Vlad	CLT-12
444	Incorporation of upper motor neurons in drug	Hande Ozdinler	TST-03
446	A Personalized Medicine Approach for ALS/I	Jeffrey Rosenfeld	DSP-10
448	Targeting of the regulatory balance between	Cyril QUESSADA	TST-33
451	Elucidating mechanisms of TDP-43 toxicity in	Emily Carroll	IVT-12
452	Therapeutic potential of The Bornavirus X pr	Gwendal Le Masson	TST-15
453	Vesicle trafficking pathways are dysregulated	Ana Candalija	HCB-05
454	A comprehensive approach to end of life disc	Paula Brockenbrough	CMS-32
455	Molecular basis of upper motor neuron dege	Hande Ozdinler	GEN-30
456	AI-led Drug Discovery identifies Nilotinib as a	Nora Markus	TST-41
457	Partitioning the genetic architecture of amyot	Iris Broce	GEN-29
458	Implementing home care respiratory protoco	Paula Brockenbrough	RNM-17
460	Chitinases as Markers of Neuroinflammation	Julian Grosskreutz	BIO-12
461	Investigating synaptic dysfunction in a C9orf	Zoe Butti	IVV-04
462	The Effect of Riluzole Oral Film on Swallowin	James Wymer	CMS-26
463	C-Reactive Protein and Disease Aggressiven	Julian Grosskreutz	BIO-13
464	Inspiratory pressurization therapy associated	Alessandra Dorca	RNM-12
465	The symptoms and impacts of MND/ALS from	Meghan McKenzie	CLT-03
466	Split finger syndrome in ALS	Masahiro Sonoo	IMG-06
467	Evidence for Generalizability of Edaravone Ef	David Ennist	EPI-13
468	Engaging ALS Research Ambassadors to He	James Berry	CLT-04
469	Residential history of volatile solvent exposur	Walter Bradley	EPI-05
470	Rapid reprogramming method differentiates	Cassandra Dennys-Rivers	DSP-09
471	The NEALS Consortium – a Collaborative Re	Tara Lincoln	CLT-01
472	Interaction (nonuniformity) of ALS progressio	Kazuko Matsuda	CLT-25
474	Long-Term Follow-Up for Patients Undergoin	Lisa Kinsley	CP-11
475	Mutations in the glycosyltransferase domain	Tobias Moll	HCB-16
476	Effect of Intravenous Infusion of Edaravone c	Hidetoshi Shimizu	CLT-42
477	Clinical correlation of MRI-based brain morpl	Krzysztof Barć	IMG-22
478	Longitudinal magneto-encephalography in ex	Rosanne Govaarts	IMG-15
479	The Addition of Rotational and Adjustable Fle	Sara Feldman	WP-22

480	The Impact of Renal or Hepatic Impairment c	Yoshinobu Nakamaru	CLT-41
481	Assessing Assistive Technology Use and Ne	Sara Feldman	WP-21
482	Radicava/Edaravone Findings in Biomarkers	James Berry	CLT-40
483	Retaining Physical Function in Amyotrophic L	Joseph Palumbo	CLT-39
484	Challenges and success of rowing across the	Heather Hayes	CP-01
485	Expression of poly(GA) and poly(PR) in iPSC	Paola Barbagallo	HCB-06
486	The Influence of Clinical Study Inclusion Crit	Jonathan Katz	CLT-07
487	Pre-clinical test of a gene therapy approach t	Thibaut MARAIS	TST-27
488	Longitudinal Analysis of CSF biomarkers for	Lucas Vu	BIO-04
490	Surveillance of using a novel, free-radical sca	Gen Sobue	CLT-38
491	Are we under dosing our patients with mid-st	Heather Hayes	CMS-08
492	Supporting Choice in Dysphagia Management	Lesley Doyle	CP-05
494	Machine Learning Model Using Insurance Cl	Wendy Agnese	EPI-10
495	Pathogenic and Functional Effects of the F11	David Medina	IVT-09
496	Premature polyadenylation and loss of the ne	Clotilde Lagier-Tourenne	HCB-17
497	Transmission of human mutant SOD1 across	Neil Cashman	IVV-25
499	Gain of toxicity from ALS/FTD-linked repeat	Sarah Mueller	IVV-40
500	Real-World Evidence of Radicava® (edaravo	Terry Heiman-Patterson	CMS-29
501	Long-read sequencing approaches to investi	Paul Valdmanis	WP-06
502	TUDCA ALS: A novel clinical trial design for	Antoniangela Cocco	CLT-17
503	Investigating changes in neuronal excitability	Dzung Do-Ha	HCB-10
504	Determining Environmental Risk Factors for	Walter Bradley	EPI-03
505	Inflammatory response to TDP-43 knockdown	Serey Naidoo	IVT-27
506	A survey of healthcare professionals on the r	Deirdre Murray	CMS-06
507	Occupational Therapist and the benefits of th	Rachael Brown	CP-24
508	Developing a Message Banking Pathway: Th	Lesley Doyle	CMS-20
509	SQSTM1 variants in familial ALS patients	Rüstem Yilmaz	GEN-21
510	Identifying how many SNIPs to get maxscore	Deirdre Murray	RNM-14
511	The effect of comorbidities in ALS prognosis	Christian Lunetta	EPI-17
512	Cyanobacterial Exposure and Neurodegener	Tanya Butt	EPI-04
513	The importance of the reception performed k	Adriana Oda	CMS-03
514	Developing cell lines from distinct ALS/MND	Jeffrey Rosenfeld	HCB-03
515	Registry of Endpoints And Validated Experie	Dara Meldrum	RNM-26
517	Longitudinal Data Collection of Combined Cl	Christian Lunetta	EPI-18
518	Structural and functional implications of corti	Thanuja Dharmadasa	DSP-08
519	Nursing driven initiative to increase tolerabil	Benjamin Brooks	CMS-27
520	Good riddance to bad rubbish: Waste dispos	Charlotte Dunne	WP-09
521	Factors that influence the tolarwnce of nonin	Vinicius Z Silva	RNM-19
522	Comparison study of the anatomical redistrib	Kai Kysenius	IVV-31
523	Copper malfunction is a pervasive feature of	James Hilton	HCB-27
524	Ferroptotic stress induces neurotoxic astrocy	Jeffrey Liddell	TST-12
527	Animal assisted activity with service dogs "Or	YUTAKA OGINO	CP-18
528	Nucleocytoplasmic transport defects are indi	Julie Atkin	HCB-09
530	Investigating TDP-43 mislocalisation using ne	Anthony Cook	WP-10
531	Motor Neuron Morphogenesis is controlled b	Georg Haase	IVV-19
532	The world according to the D50 model of AL	Julian Grosskreutz	DSP-06

533	Significant Events during ALS progression	Julian Grosskreutz	DSP-07
538	In-vivo dampening the metabotropic glutamate	Giambattista Bonanno	IVV-21
539	Engineering and enhancing the therapeutic p	Alinda Fernandes	TST-32
540	Concurrent hypomorphic cytoplasmic dynein	Majid Hafezparast	IVT-13
541	Efficacy of Edaravone in Korean Amyotrophic	Jin-Sung Park	CLT-37
542	The impact of respiratory muscle training on	Kathryn Watson	RNM-10
543	UNDERSTANDING THE MOLECULAR MECHANISMS	Samar Hasnain	TST-31
545	A study of Non-motor manifestations in patients	Abhishek Chowdhury	COG-08
570	A Dying Wish: Organ Donation in MND - Ethical	Linda Sheahan	CP-32
571	Novel patient-derived 3D in vitro models of motor	Carla Cuni-Lopez	WP-07
572	High-throughput screening for the development	Valeria Colicchia	WP-24